These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28042713)

  • 21. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study.
    Salvatore S; Nappi RE; Zerbinati N; Calligaro A; Ferrero S; Origoni M; Candiani M; Leone Roberti Maggiore U
    Climacteric; 2014 Aug; 17(4):363-9. PubMed ID: 24605832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Local estrogen therapy--clinical implications--2012 update].
    Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
    Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaginal Health: Insights, Views & Attitudes survey in Latin America (VIVA-LATAM): focus on Brazil.
    Pompei LM; Wender MCO; de Melo NR; Kulak J; Pardini D; Machado RB; Fernandes CE; Palacios S; Nappi RE
    Climacteric; 2021 Apr; 24(2):157-163. PubMed ID: 32869682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recognizing and treating urogenital atrophy in postmenopausal women.
    Goldstein I
    J Womens Health (Larchmt); 2010 Mar; 19(3):425-32. PubMed ID: 20156082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
    Nappi RE; Palacios S
    Climacteric; 2014 Feb; 17(1):3-9. PubMed ID: 24423885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
    Portman DJ; Bachmann GA; Simon JA;
    Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of raloxifene on sexual function in postmenopausal women.
    Kessel B; Nachtigall L; Plouffe L; Siddhanti S; Rosen A; Parsons A
    Climacteric; 2003 Sep; 6(3):248-56. PubMed ID: 14567773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
    North American Menopause Society
    Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
    Labrie F; Montesino M; Archer DF; Lavoie L; Beauregard A; Côté I; Martel C; Vaillancourt M; Balser J; Moyneur E;
    Climacteric; 2015; 18(6):817-25. PubMed ID: 26517756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
    Tan O; Bradshaw K; Carr BR
    Menopause; 2012 Jan; 19(1):109-17. PubMed ID: 22011753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macro-regional variation in attitudes toward and experiences of vulvar and vaginal atrophy among Italian post-menopausal women: a post hoc analysis of REVIVE survey data.
    Nappi RE; Particco M; Biglia N; Cagnacci A; Di Carlo C; Luisi S; Paoletti AM
    Gynecol Endocrinol; 2017 May; 33(5):389-394. PubMed ID: 28277131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
    Wurz GT; Kao CJ; DeGregorio MW
    Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of postmenopausal vaginal atrophy with 10-μg estradiol vaginal tablets.
    Panay N; Maamari R
    Menopause Int; 2012 Mar; 18(1):15-9. PubMed ID: 22393176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaginal anatomy and sexual function.
    Weber AM; Walters MD; Schover LR; Mitchinson A
    Obstet Gynecol; 1995 Dec; 86(6):946-9. PubMed ID: 7501345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical and patient attitude towards vaginal atrophy: the AGATA study.
    Palma F; Della Vecchia E; Cagnacci A;
    Climacteric; 2016 Dec; 19(6):553-557. PubMed ID: 27736240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of vaginal penetration difficulties on the sexual functioning of women and their male partners.
    Elran E; Bronner G; Uziel N; Eli I; Kitrey ND; Raviv G
    Eur J Contracept Reprod Health Care; 2014 Oct; 19(5):352-8. PubMed ID: 24999222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Glycine max (L.) Merr. soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled trial.
    Lima SM; Bernardo BF; Yamada SS; Reis BF; da Silva GM; Galvão MA
    Maturitas; 2014 Jul; 78(3):205-11. PubMed ID: 24856055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of HIV infection among Dutch expatriates in sub-Saharan Africa.
    Houweling H; Coutinho RA
    Int J STD AIDS; 1991; 2(4):252-7. PubMed ID: 1911956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress and prospects in treating postmenopausal vaginal atrophy.
    Winneker RC; Harris HA
    Clin Pharmacol Ther; 2011 Jan; 89(1):129-32. PubMed ID: 20944561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.